EMEA-003104-PIP01-21 - paediatric investigation plan
Favezelimab
Pembrolizumab
PIPHuman
Key facts
Active Substance
Favezelimab
Pembrolizumab
Therapeutic area
Oncology
Decision number
P/0009/2022
PIP number
EMEA-003104-PIP01-21
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms and melanoma)